Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Roivant (Nasdaq: ROIV) will report second-quarter financial results for the period ended September 30, 2025 and provide a business update on Monday, November 10, 2025. The company will host a live conference call and webcast at 8:00 a.m. ET. Investors can register to access the call by phone and view presentation and webcast details under Events & Presentations on Roivant's investor website. An archived webcast will be available on Roivant's website after the conference call.
Roivant (Nasdaq: ROIV) riferirà i risultati finanziari del secondo trimestre per il periodo terminato il 30 settembre 2025 e fornirà un aggiornamento sull'attività il lunedì 10 novembre 2025. L'azienda ospiterà una conferenza telefonica in diretta e una trasmissione webcast alle 8:00 a.m. ET. Gli investitori possono registrarsi per accedere alla chiamata telefonica e visualizzare i dettagli della presentazione e della webcast nella sezione Eventi e presentazioni sul sito degli investitori di Roivant. Una versione archiviata del webcast sarà disponibile sul sito di Roivant dopo la conference call.
Roivant (Nasdaq: ROIV) reportará los resultados financieros del segundo trimestre para el periodo terminado el 30 de septiembre de 2025 y proporcionará una actualización comercial el lunes 10 de noviembre de 2025. La empresa llevará a cabo una conferencia telefónica en directo y una transmisión web en directo a las 8:00 a.m. ET. Los inversores pueden registrarse para acceder a la llamada por teléfono y ver los detalles de la presentación y la webcast en la sección de Eventos y Presentaciones en el sitio de inversores de Roivant. Una transmisión web archivada estará disponible en el sitio de Roivant después de la conferencia.
Roivant (Nasdaq: ROIV) 은 2025년 9월 30일 종료된 분기의 2분기 재무 실적을 발표하고 2025년 11월 10일 월요일에 비즈니스 업데이트를 제공합니다. 회사는 동부 시간 8:00에 라이브 컨퍼런스 콜과 웹캐스트를 주최합니다. 투자자들은 Roivant의 투자자 웹사이트의 이벤트 및 발표 섹션에서 전화로 접속하고 프레젠테이션 및 웹캐스트 세부 정보를 확인하려 등록할 수 있습니다. 컨퍼런스콜 종료 후 Roivant의 웹사이트에서 보관된 웹캐스트를 이용하실 수 있습니다.
Roivant (Nasdaq : ROIV) annoncera les résultats financiers du deuxième trimestre pour la période se terminant le 30 septembre 2025 et fournira une mise à jour commerciale le lundi 10 novembre 2025. L'entreprise animera une conférence téléphonique en direct et une webdiffusion à 8 h 00 HNE. Les investisseurs peuvent s'inscrire pour accéder à l'appel par téléphone et consulter les détails de la présentation et de la webdiffusion dans la rubrique Événements et Présentations sur le site investisseurs de Roivant. Une webdiffusion archivée sera disponible sur le site de Roivant après la conférence.
Roivant (Nasdaq: ROIV) wird die Ergebnisse für das zweite Quartal für den Zeitraum bis zum 30. September 2025 bekannt geben und am Montag, den 10. November 2025 ein Update zum Geschäft vorlegen. Das Unternehmen wird eine Live-Konferenzschaltung und einen Webcast um 8:00 Uhr ET durchführen. Investoren können sich registrieren, um die telefonische Teilnahme zu ermöglichen und Details zur Präsentation und zum Webcast unter Veranstaltungen & Präsentationen auf Roivants Investorenseite zu sehen. Ein archivierter Webcast wird nach der Telefonkonferenz auf Roivants Website verfügbar sein.
Roivant (بورصة ناسداك: ROIV) ستعلن عن نتائجها المالية للربع الثاني للفترة المنتهية في 30 سبتمبر 2025 وتقدم تحديثاً عن الأعمال في الاثنين 10 نوفمبر 2025. ستستضيف الشركة مكالمة هاتفية حية وبثاً مباشراً عبر الويب في 8:00 صباحاً بتوقيت شرق الولايات المتحدة. يمكن للمستثمرين التسجيل للوصول إلى الهاتف ومشاهدة تفاصيل العرض والبث عبر قسم الأحداث والعروض في موقع Roivant للمستثمرين. سيكون بث الويب المحفوظ متاحاً على موقع Roivant بعد المكالمة.
Roivant（纳斯达克股票代码：ROIV） 将公布截至2025年9月30日的第二季度财务业绩，并于2025年11月10日，星期一提供业务更新。公司将于美东时间8:00举行现场电话会议和网络广播。投资者可在 Roivant 的投资者网站的 事件与披露栏目注册以通过电话接入并查看演示文稿和网络广播的详情。会议结束后，Roivant 的网站将提供归档网络广播。
- None.
- None.
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results for the second quarter ended September 30, 2025, and provide a business update.
To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant
Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit https://roivant.com.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
When will Roivant (ROIV) report its Q2 2025 financial results?
How can investors join the Roivant (ROIV) November 10, 2025 conference call?
What period do the Roivant (ROIV) results cover for the November 10, 2025 report?
Will a recording of the Roivant (ROIV) November 10, 2025 webcast be available after the call?
Where on Roivant's website can I find the November 10, 2025 presentation and webcast details?
